The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.
Judith Balmaña
No relevant relationships to disclose
Nadine M. Tung
No relevant relationships to disclose
Steven J. Isakoff
No relevant relationships to disclose
Begoña Graña
No relevant relationships to disclose
Paula D. Ryan
No relevant relationships to disclose
Rezvan Rafi
Employment or Leadership Position - AstraZeneca
Michael Tracy
Employment or Leadership Position - AstraZeneca
Eric Winer
No relevant relationships to disclose
José Baselga
Consultant or Advisory Role - AstraZeneca
Judy Ellen Garber
No relevant relationships to disclose